1. The Swiss Primary Ciliary Dyskinesia registry: objectives, methods and first results
- Author
-
Gaudenz Hafen, Florian S. Halbeisen, Romain Lazor, Juerg Barben, Philipp Latzin, Claudia E. Kuehni, Christian F. Clarenbach, Nicolas Regamey, Myrofora Goutaki, Maura Zanolari, Carmen Casaulta, Marc O. Eich, Stefan A. Tschanz, Elisabeth Maurer, and University of Zurich
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,610 Medicine & health ,2700 General Medicine ,Disease ,Patient identification ,Rare Diseases ,360 Social problems & social services ,Epidemiology ,Prevalence ,otorhinolaryngologic diseases ,medicine ,Humans ,Cilia ,Registries ,Pulmonologists ,Lung function ,Primary ciliary dyskinesia ,Kartagener Syndrome ,business.industry ,medicine.disease ,Structure and function ,Clinical Practice ,Female ,10178 Clinic for Pneumology ,business ,Switzerland - Abstract
Primary Ciliary Dyskinesia (PCD) is a rare hereditary, multi-organ disease caused by defects in ciliary structure and function. It results in a wide range of clinical manifestations, most commonly in the upper and lower airways. Central data collection in national and international registries is essential to studying the epidemiology of rare diseases and filling in gaps in knowledge of diseases such as PCD. For this reason, the Swiss Primary Ciliary Dyskinesia Registry (CH-PCD) was founded in 2013 as a collaborative project between epidemiologists and adult and paediatric pulmonologists.The registry records patients of any age, suffering from PCD, who are treated and resident in Switzerland. It collects information from patients identified through physicians, diagnostic facilities, and patient organisations. The registry dataset contains data on diagnostic evaluations, lung function, microbiology and imaging, symptoms, treatments, and hospitalizations.By May 2018, CH-PCD has contacted 566 physicians of different specialties and identified 134 patients with PCD. At present this number represents an overall 1 in 63,000 prevalence of people diagnosed with PCD in Switzerland. Prevalence differs by age and region; it is highest in children and adults younger than 30 years, and in Espace Mittelland. The median age of patients in the registry is 25 years (range 5-73), and 49 patients have a definite PCD diagnosis based on recent international guidelines. Data from CH-PCD are contributed to international collaborative studies and the registry facilitates patient identification for nested studies.CH-PCD has proven to be a valuable research tool that already has highlighted weaknesses in PCD clinical practice in Switzerland. Development of centralised diagnostic and management centres and adherence to international guidelines are needed to improve diagnosis and management—particularly for adult PCD patients.
- Published
- 2018
- Full Text
- View/download PDF